As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks to the surprising resilience of AbbVie’s autoimmune blockbuster. Now, in the face of lackluster Cytelzo sales, Boehringer has decided to prune its ranks in the U.S. and adopt […]
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Excitement grows as the FDA’s first approval for MASH treatment nears commercialization, according to Spherix Global Insights. Exton, PA., April 5, 2024 – As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) is poised to make a sizable impact on a condition with substantial unmet need. As […]
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
Research conducted by Spherix Global Insights reveals Retinal Specialists likely to adopt gene therapies. Exton, PA., March 19, 2024 – Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and […]
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use of SGLT2 inhibitors, TARPEYO (Calliditas), and FILSPARI (Travere Therapeutics). EXTON, Pa., March 12, 2024 – The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of […]
How Do Companies Avert Further Frustration Among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements. EXTON, PA., March 12, 2024 — For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming months may prove equally heart-wrenching. They face the daunting responsibility of informing patients and caregivers that not […]
Charting New Paths: Non-TNF’s Evolving in Rheumatoid Arthritis Market
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and expand their market share, according to Spherix Global Insights. EXTON, PA., February 23, 2024 — Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer […]
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
Adoption of Leqembi is even slower than expected. EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical community and among families nationwide. The debut of Aduhelm from Biogen in 2021 brought with it a wave of […]
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
Earlier screening will be needed in the age of biomarkers. EXTON, PA., February 16, 2024 — Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this degenerative condition. With gene therapies emerging as an exciting potential mechanism of action (MOA) for future treatment, their […]
Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class, first established by Novartis’ Cosentyx and Eli Lilly’s Taltz, according to Spherix Global Insights. EXTON, PA., January 22, 2024 — Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment […]
Spherix Global Insights Delivers Cheeriodicals to Dialysis Patients
[Exton, PA., January 18, 2024]—Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis patients at local dialysis clinics in West Chester and Phoenixville, PA. A team of nearly approximately 60 employees from Spherix Global Insights came together to volunteer their time, packing 200 Cheeriodicals care bags for patients […]
